FDA dispute resolution
This article was originally published in The Gray Sheet
June 16 direct-to-final rule implementing Sec. 404 of the FDA Modernization Act is withdrawn "because the agency received significant adverse comment." The rule, issued in compliance with the scientific dispute resolution provision of FDAMA, provided that controversies should be resolved with "established mechanisms." It also amended existing regulations to allow manufacturers of drugs and devices to request review of a scientific controversy by an advisory panel. The Health Industry Manufacturers Association had called on FDA in Aug. 31 comments to withdraw the rule because it would have failed to follow the law and been ineffective in implementing Congress' intent ("The Gray Sheet" Sept. 14, p. 9)
You may also be interested in...
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.